跳至主要内容
临床试验/NCT02474381
NCT02474381Unknown不适用

Efficacy Study of Autologous Endothelial Progenitor Cells Treatment of Diabetic Foot With Infrapopliteal Arterial Stenosis/Occlusion

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2012年12月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
60
试验地点
1
主要终点
Infrapopliteal arterial patency of the affected extremity

研究概览

简要总结

The vascular pathologic basis of diabetic foot include arterial obstruction and micro-circulation defects.The latest technology of arterial reconstruction can only rebuild blood flow of anterior,posterior tibial artery and peroneal artery.Endothelial progenitor cells have been proved to integrate into damaged vascular endothelium and improve vasculogenesis in vitro and in animal experiment.Therefore endothelial progenitor cells are supposed to improve the micro-circulation status of diabetic foot patients.In this trial,the investigators recuit diabetic foot patients with infrapopliteal arterial obstructive disease,treat them with autologous endothelial progenitor cells after intraluminal intervention,and observe the therapeutic efficacy comparing to single intraluminal intervention.

详细描述

Study design The study was a prospective, non-random¬ized trial conducted at 2 centers in east China - Tenth People's Hospital of Tongji University and Nanjing First Hospital. The ethic committee at each center approved the protocol, and all patients provided written informed consent. All patients enrolled were assigned to CD133+ cells treatment group (CD133+ group) and control group of their own volition. This study is to evaluate the efficacy and immune-regulatory impact of intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD.

Patient enrollment and grouping Diabetic PAD patients aged ≥18 years with Rutherford categories 2 to 5 were included to assess the eligibility for this study. All patients, who agreed to participate in the study, could voluntary choose whether or not to receive autologous CD133+ progenitor cell treatment.

In this study, CD133+cells were used to stimulate angiogenesis and reconstruct efficient microvascular blood supply, therefore similar hemodynamic status in main branch was essential to meet homogeneityin both groups before patient entry. The candidates, who failed for intraluminal revascularization of infra-aorta (iliac and femoral-popliteal)and 1 infra-popliteal (anterior/posterior tibial, fibular) arteries of the affected limb, would be excluded from the study.

Other exclusion criterion were as follows: ① Hemoglobin < 10 mg/dl, ② creatinine clearance < 30 ml/min, ③ previous history of stem/progenitor cell therapy, ④ paralysis because of central neural system disease, ⑤ accidental amputation or bone fracture of target limb because of trauma after entry, ⑥ stop of anti-platelet medication after entry, ⑦ smoking or re-smoking after entry, ⑧ malignant tumor.

Treatment of infra-aorta & infra-popliteal artery lesion Computed tomographic angiography (CTA) was performed to firstly analyze the condition of vascular lesion and then digital subtraction angiography (DSA) was performed to precisely identify the lesions of infra-aorta and the infra-popliteal arteries before treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetic PAD patients aged ≥18 years with Rutherford categories 2 to 5

排除标准

  • Hemoglobin < 10 mg/dl
  • Creatinine clearance < 30 ml/min
  • Previous history of stem/progenitor cell therapy
  • Paralysis because of central neural system disease
  • Accidental amputation or bone fracture of target limb because of trauma after entry
  • Stop of anti-platelet medication after entry
  • Smoking or re-smoking after entry
  • Malignant tumor

结局指标

主要结局

Infrapopliteal arterial patency of the affected extremity

时间窗: Every 3 month until 1year after the treatment

Ultrasonography deployed to assess the patency

次要结局

  • Amputation rate of the affected extremity(At 6 month and 1 year after the treatment)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Maoquan Li

Chief of Interventional Department

Shanghai 10th People's Hospital

研究点 (1)

Loading locations...

相似试验

Autologous Endothelial Progenitor Cells Treatment of... | 临床试验